Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
Ampronix
GLOBETECH PUBLISHING LLC

MRI Guidance Used in Brain Cancer Drug Injection Procedure

By Medimaging International staff writers
Posted on 19 Aug 2013
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Neurosurgeons in California are among the first in the world to utilize real-time magnetic resonance imaging (MRI) guidance for delivery of gene therapy as a potential treatment for brain tumors. Using MRI navigational technology, neurosurgeons can inject Toca 511 (vocimagene amiretrorepvec), a unique investigational gene therapy, directly into a brain tumor. This new application offers a precise way to deliver a therapeutic virus designed to make the tumor vulnerable to cancer-killing drugs.

“With chemotherapy, just about every human cell is exposed to the drug’s potential side-effects. By using the direct injection approach, we believe we can limit the presence of the active drug to just the brain tumor and nowhere else in the body,” said Clark Chen, MD, PhD, chief of stereotactic and radiosurgery and vice-chairman of neurosurgery University of California (UC) San Diego School of Medicine (USA). “With MRI, we can see the tumor light up in real time during drug infusion. The rest of the brain remains unaffected so the risk of the procedure is minimized.”

Toca 511 is a retrovirus engineered to selectively replicate in cancer cells, such as glioblastomas. Toca 511 generates an enzyme that converts an antifungal drug, flucytosine (5-FC), into the anticancer drug 5-fluorouracil (5-FU). After the injection of Toca 511, the patients are treated with an investigational extended-release oral formulation of 5-FC called Toca FC. Cancer cell killing takes place when 5-FC comes into contact with cells infected with Toca 511.

“Inevitably, almost all glioblastoma patients fail currently available therapy. The challenge, in part, is knowing if current drugs are actually penetrating the tumor. This MRI-guided approach will help us deliver this drug into the tumor directly to see if the drug is working,” said Santosh Kesari, MD, PhD, lead investigator and director of neuro-oncology at UC San Diego Moores Cancer Center (USA). “This approach may lead to new treatment options for patients battling several other types of brain cancers.”

Earlier research using gene therapy to treat brain cancer was mostly limited by the failure in delivering the drug into the brain. Under normal conditions, the brain is protected by the blood-brain barrier but this natural defense mechanism also prevents drugs from reaching the cancer cells in patients with brain tumors. Fortunately, 5-FC crosses the blood-brain barrier, and direct injection of Toca 511 into the tumor provides a means to selectively generate chemotherapy within the tumor mass.

To ensure that the adequate amount of Toca 511 is delivered to the region of the tumor, neurosurgeons at UC San Diego Health System utilize state-of-the art MRI guidance, called ClearPoint, to track the delivery and injection processes in real time. The MRI-guided process provides visual validation that the desired amount of drug is delivered into the tumor and provides physicians the ability to make adjustments to optimize the location of drug delivery. The Clearpoint technology was developed by MRI Interventions (Memphis, TN, USA).

Participants in this clinical trial must be 18 years or older; have a single, recurrent Grade 3 or 4 glioma; and have had prior surgery, radiation, and chemotherapy. The MRI-based procedure is minimally invasive and all participants of the study were discharged from the hospital one day after surgery and resumed their normal daily activity.

The phase 1 trial is evaluating the safety and tolerability of Toca 511 in combination with Toca FC (5-FC, extended-release tablets), and is being developed by Tocagen, Inc. (San Diego, CA, USA).

Related Links:

University of California, San Diego Moores Cancer Center
Tocagen
MRI Interventions



Channels

Radiography

view channel

Pediatric Radiation Dose Reduction Key Factor in Selection of DR Systems

X-Ray dose reduction potential was a key factor in the decision of the Washington DC (USA) metropolitan area Children’s National Health System to install new Direct Radiography (DR) systems. The priority of Children’s National Health System was to ensure that pediatric patients would receive the lowest possible dose... Read more

Ultrasound

view channel
Image: The Lumify, app-based ultrasound system (Photo courtesy of Philips).

Philips Debuts First App-Based Ultrasound

An app-based ultrasound solution aims extending the reach of ultrasound applications using mobile technology. The app was presented at the Social Media and Critical Care conference, June, 23–26, 2015... Read more

Nuclear medicine

view channel

Hybrid Scanner Using Five Molecular Imaging Techniques Under Development

Scientists are developing a new molecular, preclinical hybrid imaging system to help find new drugs and to advance imaging research. The scanner was presented at the 2015 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI; Reston, Virginia, USA), and consists of a window for tissue observation,... Read more

General/Advanced Imaging

view channel

FDA Approves Trial for Intraoperative Image-Guided Cancer Surgery System

The US Food and Drug Administration (FDA) has provided Investigational Device Exemption (IDE) approval for company to trial a new image-guided cancer surgery system for intraoperative imaging of breast cancer. The surgical system consists of a cancer-specific molecular imaging agent, and a lightweight hand-held single-cell... Read more

Imaging IT

view channel
Image: Siemens radiation therapy Syngo.via image suite (Photo courtesy of Siemens Healthcare).

New Version of Syngo.via Supports Treatment Decision in Oncology

Siemens Healthcare has released a new version of oncology diagnostics software that helps physicians plan the best course of treatment for cancer patients. Cancer treatment requires comprehensive diagnostics,... Read more

Industry News

view channel
Image: The Westchester Medical Center in Valhalla, NY, USA (Photo courtesy of Business Wire).

Philips to Provide Multi-Year USD 500 Million in Healthcare Services in the USA

Royal Philips (Amsterdam, the Netherlands) and the Westchester Medical Center Health Network (WMCHealth; Valhalla, NY, USA) have announced USD 500 million multi-year partnership. Philips will provide... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.